Abstract
Patients with chronic wounds should receive wound treatment in addition to causative therapy. In this context, the lack of adequate evidence for wound healing products has been repeatedly discussed. Using the example of TLC-sucrose octasulfate (TLC: technology lipido-colloid), the present review shows that there is significant data with good evidence and comparability in this area. One therapeutic approach to promote wound healing is the inhibition of matrix-metalloproteinases, for example by sucrose octasulfate. For wound products containing TLC-sucrose octasulfate, several sequential clinical studies have been conducted in recent years. The WHAT study was an open randomized controlled trial (RCT) with 117 patients with venous leg ulcers (VLU). The CHALLENGE study was adouble-blind RCT with 187 patients with VLU. The SPID study was apilot study with 33patients with diabetic foot ulcers (DFU). The two prospective, multicenter clinical pilot studies NEREIDES and CASSIOPEE examined a total of 88patients with VLU in different phases of healing. In the REALITY study, apooled data analysis was performed on eight observational studies with 10,220 patients with chronic wounds of different genesis. In the double-blind, two-armed EXPLORER RCT, 240 patients with neuro-ischemic DFU were followed from first presentation until complete healing. In all studies, asignificant promotion of wound healing could be shown by the use of wound healing products with TLC-sucrose octasulfate.
Highlights
Polyhydriertes Ionogen (PHI, enthält Tegaderm Matrix (3M, Neuss, Deutschland) Rubidium, Kalzium, Zink und Kalium) signifikant; Schmerzen und Unbehagen sowie Angst und Depressionen (VAS 1,35 ± 0,53 vs. 1,54 ± 0,60; p = 0,037) nahmen ab
Using the example of TLC-sucrose octasulfate (TLC: technology lipido-colloid), the present review shows that there is significant data with good evidence and comparability in this area
One therapeutic approach to promote wound healing is the inhibition of matrixmetalloproteinases, for example by sucrose octasulfate
Summary
Joachim Dissemond1 · Matthias Augustin2 · Michael Dietlein3 · Winfried Keuthage4 · Severin Läuchli5 · Ralf Lobmann6 · Karl-Christian Münter7 · Markus Stücker8 · Jürg Traber9 · Wolfgang Vanscheidt10 · Robert Strohal. Als Grundlage für die optimale Behandlung von Patienten mit chronischen Wunden sind valide und aussagekräftige Informationen aus klinischen Studien unerlässlich. Aktuell verfügbar sind diesbezüglich jedoch nur wenige qualitativ aussagekräftige Daten mit guter Evidenz und Übertragbarkeit auf den klinischen Alltag. Eine Ausnahme stellen die Studien zu der Behandlung chronischer Wunden mit TLC(Lipidkolloid-Technologie, „technology lipido-colloid“)Sucrose Octasulfat dar. Trotz Vorliegen heterogener und oft multifaktorieller Krankheitsbilder bei chronischen Wunden konnten anhand mehrerer klinischer Studien Aussagen mit guter Evidenz für die Wirksamkeit von Wundauflagen mit TLC-Sucrose Octasulfat auf den Wundheilungsprozess getroffen werden. Dabei hat sich die Qualität der Datenlage im Laufe der Jahre kontinuierlich verbessert [1,2,3,4,5,6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
